Search Results - "Gore, S.D"

Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study by Zeidan, A, Hu, X, Long, J.B, Wang, R, Ma, X, Podoltsev, N, Huntington, S, Gore, S.D, Davidoff, A.J

Get full text

35 Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes? by Gore, S.D

Get full text

CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS) by Garcia-Manero, G, Savona, M.R, Gore, S.D, Scott, B.L, Cogle, C.R, Boyd, T, Conkling, P, Hetzer, J, Dong, Q, Kumar, K, Ukrainskyj, S.M, Skikne, B.S

Get full text

29 In vitro basis for treatment with hypomethylating agents and HDAC inhibitors: Can epigenetic changes be used to monitor treatment? by Gore, S.D

Get full text

99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) by Garcia-Manero, G, Savona, M.R, Gore, S.D, Cogle, C.R, Conkling, P, Hetzer, J, Dong, Q, Ukrainskyj, S.M, Skikne, B.S

Get full text

80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY by Wane, R, Zeidan, A, Soulos, P.R, Yu, J.B, Davidoff, A.J, Gore, S.D, Gross, C.P, Ma, X

Get full text

145 Erythropoietic-stimulating agents (ESAs) are not associated with a transient risk of deep venous thrombosis (DVT) in myelodysplastic syndromes (MDS) by Sato, M, Smith, S.R. Weiss, Davidoff, A, Baer, M.R, Ke, X, McNally, D, Gore, S.D

Get full text

87 Erythropoietic-stimulating agents (ESAs) in the real world: do ESAs promote transfusion-independence (TI) in myelodysplastic syndrome (MDS) patients? by Smith, S.R. Weiss, Sato, M, Baer, M.R, Ke, X, Gore, S.D, Davidoff, A.J

Get full text

181 Oral azacitidine is bioavailable and reduces DNA methylation at low doses in extended schedules: Phase I study results by Laille, E, Shi, T, Garcia-Manero, G, Gore, S.D, Cogle, C.R, Giordano, H, MacBeth, K.J, Skikne, B

Get full text

146 Claims-based prediction of performance status (PS) associated with erythropoietic-stimulating agent (ESA) treatment and survival in myelodysplastic syndromes (MDS) patients by Ke, X, Davidoff, A, Zuckerman, I.H, Pandya, N, Hendrick, F, Smith, S. Weiss, Baer, M.R, Gore, S.D

Get full text

43 The broad use of erythropoietic stimulating agents (ESA) for myelodysplastic syndromes (MDS) in the U.S. is not consistent with guidelines by Davidoff, A.J, Baer, M.R, Smith, S.R. Weiss, Ke, X, Bierenbaum, J, Hendrick, F, McNally, D, Gore, S.D

Get full text

105 Outcome of high risk myelodysplastic syndrome after azacytidine failure by Prebet, T, Gore, S.D, Esterni, B, Itzikson, R, Thepot, S, Beach, C.L, Fenaux, P, Vey, N

Get full text

299 SOCS1 methylation and azacitidine response in high risk myelodysplasia (MDS) and secondary acute myeloid leukemia (AML) by Prebet, T, Sun, Z, Carraway, H, Thakar, M, Greenberg, P, Czader, M, Paietta, E, Juckett, M, Erba, H, Gabrilove, J, Tallman, M, Herman, J, Gore, S.D

Get full text

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes by Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B

“…CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of…”
Get full text

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides by Zeidan, A M, Sekeres, M A, Garcia-Manero, G, Steensma, D P, Zell, K, Barnard, J, Ali, N A, Zimmerman, C, Roboz, G, DeZern, A, Nazha, A, Jabbour, E, Kantarjian, H, Gore, S D, Maciejewski, J P, List, A, Komrokji, R

“…Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are…”
Get full text

32 - Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study by Zeidan, A., Hu, X., Long, J.B., Wang, R., Ma, X., Podoltsev, N., Huntington, S., Gore, S.D., Davidoff, A.J.

Get full text

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias by Pratz, K W, Cho, E, Levis, M J, Karp, J E, Gore, S D, McDevitt, M, Stine, A, Zhao, M, Baker, S D, Carducci, M A, Wright, J J, Rudek, M A, Smith, B D

“…We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an…”
Get full text

25 - CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS) by Garcia-Manero, G., Savona, M.R., Gore, S.D., Scott, B.L., Cogle, C.R., Boyd, T., Conkling, P., Hetzer, J., Dong, Q., Kumar, K., Ukrainskyj, S.M., Skikne, B.S.

Get full text

induction by 5-azacytosine nucleosides requires DNA damage by Jiemjit, A, Fandy, T.E, Carraway, H, Bailey, K.A, Baylin, S, Herman, J.G, Gore, S.D

Get full text

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study by Fenaux, Pierre, Mufti, G.J., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., List, A.F., Gore, S.D., Seymour, J.F., Hellstrom-Lindberg, E., Bennett, J.M., Byrd, J.C., Backstrom, J.T., Zimmerman, L.S., McKenzie, D.R., Beach, C.L., Silverman, L.R.

“…Background: A previous CALGB trial (JCO 2002; 20:2429) showed a positive OS trend with AZA vs best supportive care (BSC) in MDS. The objective of this Phase…”
Get full text